Nonoperative management of hyperparathyroidism: present and future

被引:10
作者
Weigel, RJ [1 ]
机构
[1] Stanford Univ, Sch Med, Stanford, CA 94305 USA
关键词
D O I
10.1097/00001622-200101000-00007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Parathyroidectomy provides effective treatment for primary and secondary hyperparathyroidism with a predictable response of symptoms related to hypercalcemia and elevated parathyroid hormone. Calcium and vitamin D supplementation has reduced the need for parathyroidectomy in dialysis patients with secondary hyperparathyroidism. However, surgery continues to be the only effective treatment of primary hyperparathyroidism, Potential nonoperative treatments for hyperparathyroidism have included the use of estrogen replacement, bisphosphonates, and a new class of drugs known as calcimimetics, Hormone replacement therapy with estrogen has been reported to improve cortical bone density in postmenopausal women with asymptomatic or mildly symptomatic primary hyperparathyroidism. Calcimimetic agents are a new class of drugs that increase the sensitivity of the calcium receptor to ionized calcium. Initial studies have shown that calcimimetics can acutely lower parathyroid hormone levels in patients with primary and secondary hyperparathyroidism. These drugs are currently being evaluated in phase tl clinical trials. Ultimately, these medical modalities will need to be compared to parathyroidectomy in randomized controlled clinical trials. Curr Opin Oncol 2001, 13:33-38 (C) 2001 Lippincott Williams & Wilkins, Inc.
引用
收藏
页码:33 / 38
页数:6
相关论文
共 55 条
[31]  
Kirk JK, 1996, AM FAM PHYSICIAN, V54, P2053
[32]   The role of estrogen in the prevention of osteoporosis [J].
Lindsay, R .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1998, 27 (02) :399-+
[33]   EFFECT OF BISPHOSPHONATE THERAPY AND PARATHYROIDECTOMY ON THE URINARY-EXCRETION OF GALACTOSYLHYDROXYLYSINE IN PRIMARY HYPERPARATHYROIDISM [J].
LOCASCIO, V ;
BRAGA, V ;
BERTOLDO, F ;
BETTICA, P ;
FRATTA PASINI, A ;
STEFANI, L ;
MORO, L .
CLINICAL ENDOCRINOLOGY, 1994, 41 (01) :47-51
[34]   CONJUGATED ESTROGENS IN THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HYPERPARATHYROIDISM [J].
MARCUS, R ;
MADVIG, P ;
CRIM, M ;
PONT, A ;
KOSEK, J .
ANNALS OF INTERNAL MEDICINE, 1984, 100 (05) :633-640
[35]   Diagnosis and management of osteoporosis in postmenopausal women: Clinical guidelines [J].
Meunier, PJ ;
Delmas, PD ;
Eastell, R ;
McClung, MR ;
Papapoulos, S ;
Rizzoli, R ;
Seeman, E ;
Wasnich, RD .
CLINICAL THERAPEUTICS, 1999, 21 (06) :1025-1044
[36]   Video-assisted versus conventional parathyroidectomy in primary hyperparathyroidism: A prospective randomized study [J].
Miccoli, P ;
Bendinelli, C ;
Berti, P ;
Vignali, E ;
Pinchera, A ;
Marcocci, C .
SURGERY, 1999, 126 (06) :1117-1121
[37]   Calcimimetic compounds: A direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism [J].
Nemeth, EF ;
Fox, J .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1999, 10 (02) :66-71
[38]   Calcimimetics with potent and selective activity on the parathyroid calcium receptor [J].
Nemeth, EF ;
Steffey, ME ;
Hammerland, LG ;
Hung, BCP ;
Van Wagenen, BC ;
DelMar, EG ;
Balandrin, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :4040-4045
[39]  
Nemeth EF, 1996, PEDIATR NEPHROL, V10, P275
[40]   ADENYLATE-CYCLASE ACTIVITY IN HUMAN PARATHYROID TISSUES - REDUCED SENSITIVITY TO SUPPRESSION BY CALCIUM IN PARATHYROID ADENOMAS AS COMPARED WITH NORMAL GLANDS FORM NORMOCALCEMIC SUBJECTS OR NON-INVOLVED GLANDS FROM HYPERPARATHYROID SUBJECTS [J].
ONTJES, DA ;
MAHAFFEE, DD ;
WELLS, SA .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1981, 30 (04) :406-411